AliveCor’ KardiaMobile gets NICE approval to detect irregular heart rhythm symptons
KardiaMobile is the first personal ECG to be recommended by NICE for use within the National Health Service (NHS) in England and Wales
KardiaMobile is the first personal ECG to be recommended by NICE for use within the National Health Service (NHS) in England and Wales
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease
Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen
This service benefits pharmaceutical and fine chemical companies looking to optimise their reactions
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Intuitive Telepresence (ITP), facilitates remote learning, and encourages interaction and collaboration between surgeons without the need to travel
The company’s platform technology works like a compression algorithm for molecular testing and has applications in healthcare, pharmaceuticals, agriculture, animal husbandry, food safety, synthetic biology, and molecular biology research
Recent Study by Columbia University finds Mylab’s CoviSelf can detect the Omicron variant successfully
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Subscribe To Our Newsletter & Stay Updated